

EORTC and ASCO Guidelines: FN Risk Assessment

STEP 1

Assess chemotherapy regimen FN risk

| Regimen FN risk | | G-CSF use | Patient Details |
|------------------------------------|--------------------------|---------------------------------------|-----------------|
| FN risk \geq 20% | <input type="checkbox"/> | Recommended ^{1,2} | |
| Dose-dense chemotherapy is planned | <input type="checkbox"/> | Recommended ^{1,2} | |
| FN risk $<$ 20% | <input type="checkbox"/> | Consider factors below ^{1,2} | |

STEP 2

Identify factors that may increase the need for G-CSF prophylaxis

Treatment intent

| | |
|---|--------------------------|
| Treatment may be curative ^{1,2} | <input type="checkbox"/> |
| Treatment may prolong survival ^{1,2} | <input type="checkbox"/> |

Chemotherapy delivery intent

| | |
|--|--------------------------|
| Chemotherapy reductions/delays are associated with a poor prognosis ^{1,2} | <input type="checkbox"/> |
|--|--------------------------|

Patient-related factors that may increase FN risk

| | |
|---|--------------------------|
| Age $>$ 65 years ^{1,2} | <input type="checkbox"/> |
| Poor performance status ^{1,2} | <input type="checkbox"/> |
| Advanced disease ^{1,2} | <input type="checkbox"/> |
| Serious comorbidities ¹ | <input type="checkbox"/> |
| Cytopenias due to tumour bone marrow involvement ¹ | <input type="checkbox"/> |
| Female gender ² | <input type="checkbox"/> |
| Haemoglobin $<$ 12 g/dL ² | <input type="checkbox"/> |
| Poor nutritional status ^{1,2} | <input type="checkbox"/> |
| Combined chemoradiotherapy ¹ | <input type="checkbox"/> |
| Previous episode of FN ^{1,2} | <input type="checkbox"/> |
| Open wounds or active infections ¹ | <input type="checkbox"/> |

STEP 3

Overall FN risk assessment

| | | |
|---------------------------|----------------------------------|-------------------------------------|
| Overall FN risk | $<$ 20% <input type="checkbox"/> | \geq 20% <input type="checkbox"/> |
| Physician signature _____ | Date _____ | |